Shanghai Runda Medical Technology Co P/TBV
The Price to Tangible Book Value (P/TBV) of Shanghai Runda Medical Technology Co (603108.SS) as of Oct 11, 2026 is 4.78. In the previous year, Price to Tangible Book Value (P/TBV) was 4.23 — a change of 13.04% (higher).
Get this data via API
Financial Data API
P/TBV
4.78
YoY
13.04%
Last updated:
The Shanghai Runda Medical Technology Co P/TBV history
3 Years
10 Years
25 Years
Max
| YEAR | P/TBV | YoY |
|---|---|---|
| 4.78 | +13.04% | |
| 4.23 | -3.68% | |
| 4.39 | -16.43% | |
| 5.25 | -18.24% | |
| 6.42 | -9.94% | |
| 7.13 | -26.78% | |
| 9.74 | -17.17% | |
| 11.76 | -28.56% | |
| 16.46 | +173.70% | |
| 6.01 | -44.18% | |
| 10.78 | -49.69% | |
| 21.42 | — |
Shanghai Runda Medical Technology Co Stock analysis
Frequently Asked Questions about Shanghai Runda Medical Technology Co stock
Price to Tangible Book Value (P/TBV) of Shanghai Runda Medical Technology Co is 4.78 in 2025.
Price to Tangible Book Value (P/TBV) of Shanghai Runda Medical Technology Co changed from 4.23 to 4.78, representing a 13.04% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Shanghai Runda Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.
P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.
To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).
A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Shanghai Runda Medical Technology Co with sector peers and the industry average to assess whether it is attractive.
Valuation — Shanghai Runda Medical Technology Co
All Key Metrics — Shanghai Runda Medical Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth